Woggon 1978.

Methods	Allocation: randomised. Blindness: double. Duration: 30 days. Setting: inpatient.
Participants	Diagnosis: schizophrenia (n = 5 hebephrenic; n = 29 paranoid, acute schizophrenic episode; n = 2 residual; n = 2 schizo‐affective psychosis; n = 1 other paranoid syndromes). N = 40. Age: mean ˜ 39 years. Sex: 20F, 20M. History: inpatient; duration of illness 8.7 ± 10.9 years (bromperidol); 10.1 ± 8.0 (perphenazine). Included: no details. Excluded: no details. Consent: not stated.
Interventions	1. Perphenazine: capsules of 3 mg; mean 20 mg/day in two administrations; maximum 24 mg daily, n = 20. 2. Bromperidol: capsules of 1 mg; mean 6 mg/day in two administrations; maximum 8 mg daily, n = 20. Additional medication: antiparkinsonian drugs; additional neuroleptics (promazine and levomepromazine); hypnotics (chloralhydrate; nitrazepam; flunitrazepam).
Outcomes	Leaving the study early. Global state: no better or worse. Adverse events. Unable to use ‐ Mental state: AMP (no SD). Lab data: not reported.
Notes
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Randomised: no further details.
Allocation concealment (selection bias)	Unclear risk	No details.
Blinding (performance bias and detection bias) All outcomes	Unclear risk	Double‐blind: no further details.
Incomplete outcome data (attrition bias) All outcomes	Low risk	None detected.
Selective reporting (reporting bias)	High risk	No means or SDs reported for continuous outcomes and scale data.
Other bias	Unclear risk	Funding: no details. Raters: not stated to be independent of treatment.